-
Here's Why Seattle Genetics' Adcetris Is A $2 Billion Product
Wednesday, September 7, 2016 - 10:50am | 370Read More...Morgan Stanley’s Andrew S. Berens believes Seattle Genetics, Inc. (NASDAQ: SGEN)'s Adcetris is a $2 billion products, with growth primarily being driven by higher usage in transplant settings, as well as a move to front-line lymphoma treatment. Berens initiated coverage of the company with an...
-
Morgan Stanley Upgrades Intercept Pharma, Maintains $100 Target
Friday, January 29, 2016 - 9:56am | 338Read More...Intercept Pharmaceuticals Inc (NASDAQ: ICPT) shares have declined 63.88 percent over the past six months, reaching a low of $99.32 on January 28. Morgan Stanley’s Andrew S. Berens has upgraded the rating on the company from Underweight to Equal-Weight, with a price target of $100....
-
Morgan Stanley Sees 33% Downside At Intercept Pharma, Increased Risk
Thursday, October 29, 2015 - 9:54am | 288Read More...Shares of Intercept Pharmaceuticals Inc (NASDAQ: ICPT) have declined 40.3 percent over the past three months, from a high of $274.94 on July 28. Morgan Stanley's Andrew S. Berens has maintained an Underweight rating on the company, while lowering the price target from $165 to $110....
-
Morgan Stanley Calls ZS Pharma 'Best In Class,' Upgrades Stock
Friday, October 23, 2015 - 9:55am | 323Read More...The share price of ZS Pharma Inc (NASDAQ: ZSPH) has increased 53.8 percent year to date, reaching a high of $76.99 on September 11. Morgan Stanley’s Andrew S. Berens has upgraded the rating on the company from Equal-weight to Overweight, while raising the price target from $67 to $76...
